SMAD2 and pancreatic neoplasm: Shown to increase the sensitivity to gemcitabine in pancreatic cancer by inhibiting epithelial-mesenchymal transition, possibly mediated through its targeting of SMAD2/4 which is involved in TGF-β signaling (Hiramoto et al., 2017)